EUVIMEDEUVIMED entdecken
MetaanalyseOpen Access · CC BY-NC-ND 4.0

Differential treatment effect between younger and older adults for new cancer therapies in solid tumors supporting US Food and Drug Administration approval between 2010 and 2021

Brooke E Wilson iD, Alexandra Desnoyers, Michelle B Nadler, Eitan Amir, Christopher M Booth iD

Cancer · 2023

DOI: 10.1002/cncr.34911 ↗

Kurz gefasst

Metaanalyse in der Zeitschrift Cancer, 2023. Verfasst von Brooke E Wilson und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Oncology, Queen's University, Kingston, Ontario, Canada. Hauptthemen laut MEDLINE: Antineoplastic Agents, Breast Neoplasms. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 23 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Over one half of cancer diagnoses occur in patients aged 65 and older. The authors quantified how treatment effects differ between older and younger patients in oncology registration trials.

Methods

The authors performed a retrospective cohort study of registration trials supporting US Food and Drug Administration approval of cancer drugs (from January 2010 to December 2021). The primary outcome was differential treatment effect by age (younger than 65 years vs. 65 years or older) for progression‐free survival and overall survival. Random effects meta‐analysis and a pairwise comparison of outcomes by age group also were performed.

Results

Among 263 trials that met the inclusion criteria, 120 trials with 153 end points and 83,152 patients presented age‐specific outcome data. Among the included randomized patients, 38% were aged 65 years and older compared with an incidence proportion of 55% in data from the National Cancer Institute's Surveillance, Epidemiology, and End Results program. Studies evaluating prostate cancer had the highest representation of patients aged 65 years or older (73%), whereas breast cancer studies had the lowest (20%). There were no changes in the proportion of patients aged 65 years or older over time ( p = .86). Only 7% of end points showed a statistically significant interaction between outcome and age group. In a pooled analysis, there was an association between treatment effect and age for progression‐free survival that approached but did not meet significance (hazard ratio, 0.95; p = .06), and there was no difference for overall survival (hazard ratio, 0.97; p = .79).

Conclusions

Older adults remain under‐represented in oncology registration trials. Significant differences in outcomes by age group were uncommon in individual trials and pooled analyses. However, clinical trial participants differ from real‐world patients older than 65 years, and increased enrollment and ongoing research into differential treatment effects by age are needed.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antineoplastic AgentsBreast NeoplasmsAgedHumansMaleMiddle AgedDrug ApprovalMedical OncologyRetrospective StudiesUnited StatesUnited States Food and Drug AdministrationFemale

Stichwörter der Autor:innen

drug approvalgeriatric oncologymedical oncologyolder adultsregulatory approvals

Substanzen

Antineoplastic Agents

Autor:innen und Institutionen

  • Department of Oncology, Queen's University, Kingston, Ontario, Canada.
  • Division of Cancer Care and Epidemiology, Queen's Cancer Research Institute, Kingston, Ontario, Canada.
  • School of Population Health, Faculty of Medicine and Health, University of New South Wales, Sydney, New South Wales, Australia.
  • Centre Hospitalier Universitaire de Quebec-Université Laval, Hôpital Saint-Sacrement, Centre des Maladies du Sein Deschênes-Fabia, Quebec, Quebec, Canada.
  • Department of Medical Oncology and Haematology, Princess Margaret Hospital, University of Toronto, Toronto, Ontario, Canada.

ORCID-Profile: Brooke E Wilson, Christopher M Booth

Zitieren

APA

Wilson, B. E., Desnoyers, A., Nadler, M. B., Amir, E., & Booth, C. M. (2023). Differential treatment effect between younger and older adults for new cancer therapies in solid tumors supporting US Food and Drug Administration approval between 2010 and 2021. Cancer. https://doi.org/10.1002/cncr.34911

Vancouver

Wilson BE, Desnoyers A, Nadler MB, Amir E, Booth CM. Differential treatment effect between younger and older adults for new cancer therapies in solid tumors supporting US Food and Drug Administration approval between 2010 and 2021. Cancer. 2023. doi:10.1002/cncr.34911

BibTeX
@article{Wilson2023,
  author = {Wilson, Brooke E and Desnoyers, Alexandra and Nadler, Michelle B and Amir, Eitan and Booth, Christopher M},
  title = {Differential treatment effect between younger and older adults for new cancer therapies in solid tumors supporting US Food and Drug Administration approval between 2010 and 2021},
  journal = {Cancer},
  year = {2023},
  doi = {10.1002/cncr.34911}
}
Kostenlos starten →